Biotech · Private company
Ratio Therapeutics, Inc.
Track this companyFree. Adds Ratio Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials32 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- [Ac 225]RTX-2358Phase 1 · Advanced Soft Tissue SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- [Cu64]LNTH-1363SPhase 1 · Advanced Soft Tissue SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- Granzyme-B targeted [64Cu]-labeled PET radiotracerPhase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- PSMA-Targeted [In-111]-Labeled Trillium CompoundPhase 1 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- PTI-122Phase 1 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy VolunteersEARLY_PHASE1 · RECRUITING · started Jul 8, 2026ClinicalTrials.gov NCT07774650 · fetched Nov 12, 2026
- Actinium Therapy for Late-stage Aggressive SarcomasPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 12, 2025ClinicalTrials.gov NCT07156565 · fetched Nov 12, 2026
- Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate CancerEARLY_PHASE1 · COMPLETED · started Dec 8, 2022ClinicalTrials.gov NCT05773703 · fetched Nov 12, 2026